Arctium lappa ameliorates endothelial dysfunction in rats fed with high fat/cholesterol diets

BMC Complementary and Alternative Medicine

Ho Sub Lee¹  Dae Gill Kang¹  Jin Sook Kim²  Guk Hyun Cho³  Deok Ho Choi³  Yun Jung Lee¹ 

[1] Hanbang Body-fluid Research Center, Wonkwang University, Shinyong-dong, Iksan, Jeonbuk 570-749, Republic of Korea;Korea Institute of Oriental Medicine, Jeonmin-dong, Yusung-gu, Daejeon 305-811, Republic of Korea;College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, Shinyong-dong, Iksan, Jeonbuk 570-749, Republic of Korea

关键词: Inflammation;    Vasorelaxation;    Hypertension;    Hyperlipidemia;    Arctium lappa;   

Others  :  1232099
DOI  :  10.1186/1472-6882-12-116

 received in 2011-09-23, accepted in 2012-07-30,  发布年份 2012

【 摘 要 】

Background

Arctium lappa L. (Asteraceae), burdock, is a medicinal plant that is popularly used for treating hypertension, gout, hepatitis, and other inflammatory disorders. This study was performed to test the effect of ethanol extract of Arctium lappa L. (EAL) seeds on vascular reactivity and inflammatory factors in rats fed a high fat/cholesterol diet (HFCD).

Method

EAL-I (100 mg·kg⁻¹/day), EAL-II (200 mg·kg⁻¹/day), and fluvastatin (3 mg·kg⁻¹/day) groups initially received HFCD alone for 8 weeks, with EAL supplementation provided during the final 6 weeks.

Results

Treatment with low or high doses of EAL markedly attenuated plasma levels of triglycerides and augmented plasma levels of high-density lipoprotein (HDL) in HFCD-fed rats. Chronic treatment with EAL markedly reduced impairments of acetylcholine (ACh)-induced relaxation of aortic rings. Furthermore, chronic treatment with EAL significantly lowered systolic blood pressure (SBP) and maintained smooth and flexible intimal endothelial layers in HFCD-fed rats. Chronic treatment with EAL suppressed upregulation of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and E-selectin in the aorta. Chronic treatment with EAL also suppressed increases in matrix metalloproteinase (MMP)-2 expression. These results suggested that EAL can inhibit HFCD-induced vascular inflammation in the rat model.

Conclusion

The present study provides evidence that EAL ameliorates HFCD-induced vascular dysfunction through protection of vascular relaxation and suppression of vascular inflammation.

【 授权许可】

   
2012 Lee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Stokes KY, Cooper D, Tailor A, Granger DN: Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med 2002, 33:1026-1036.
• [2]Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol 2003, 139:1289-1296.
• [3]Figueroa XF, Poblete MI, Boric MP, Mendizábal VE, Adler-Graschinsky E, Huidobro-Toro JP: Clonidine-induced nitric oxide-dependent vasorelaxation mediated by endothelial alpha(2)-adrenoceptor activation. Br J Pharmacol 2001, 134:957-968.
• [4]Babaei S, Picard P, Ravandi A, Monge JC, Lee TC, Cernacek P, Stewart DJ: Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 2000, 48:158-167.
• [5]Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ 3rd, Stein EA, Lupien PJ, Brewer HB Jr, Raper SE: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995, 1:1148-1154.
• [6]Marsh MM, Walker VR, Curtiss LK, Banka CL: Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. J Lipid Res 1999, 40:893-900.
• [7]Nishimatsu H, Suzuki E, Satonaka H, Takeda R, Omata M, Fujita T, Nagai R, Kitamura T, Hirata Y: Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol Heart Circ Physiol 2005, 288:1770-1776.
• [8]Spady DK, Woollett LA, Dietschy JM: Regulation of plasma LDL-cholesterol levels by dietary cholesterol and fatty acids. Annu Rev Nutr 1993, 13:355-381.
• [9]Skretteberg PT, Grundvold I, Kjeldsen SE, Erikssen JE, Sandvik L, Liestøl K, Erikssen G, Pedersen TR, Bodegard J: HDL-cholesterol and prediction of coronary heart disease: Modified by physical fitness? A 28-year follow-up of apparently healthy men. Atherosclerosis 2012, 220:250-256.
• [10]Andreotti F, Porto I, Crea F, Maseri A: Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 2002, 87:107-112.
• [11]Blankenberg S, Barbaux S, Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis 2003, 170:191-203.
• [12]Park SY, Hong SS, Han XH, Hwang JS, Lee D, Ro JS, Hwang BY: Lignans from Arctium lappa and their inhibition of LPS-induced nitric oxide production. Chem Pharm Bull (Japan) 2007, 55:150-152.
• [13]Maruta Y, Kawabata J, Niki R: Antioxidative caffeoylquinic acid derivatives in the roots of burdock (Arctium lappa L.). J Agric Food Chem 1995, 43:2592-2595.
• [14]Iwakami S, Wu JB, Fazuka Y, Sankawa W: Platelet activating factor (PAF) Antagonists contained in medicinal plants: Lignans and sesquiterpenes. Chem Pharm Biol 1992, 40:1196-1198.
• [15]Tamayo C, Richardson MA, Diamond S, Skoda I: The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res 2000, 14:1-14.
• [16]Kang DG, Lee JK, Choi DH, Sohn EJ, Moon MK, Lee HS: Vascular relaxation by the methanol extract of Sorbus cortex via NO-cGMP pathway. Biol Pharm Bull 2005, 28:860-864.
• [17]Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL: Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999, 104:447-457.
• [18]Choi DH, Lee YJ, Kim JS, Kang DG, Lee HS: Cynanchum wilfordii ameliorates hypertension and endothelial dysfunction in rats fed with high fat/cholesterol diets. Immunopharmacol Immunotoxicol 2012, 34:4-11.
• [19]Choi DH, Lee YJ, Oh HC, Cui YL, Kim JS, Kang DG, Lee HS: Improved Endothelial Dysfunction by Cynanchum wilfordii in Apolipoprotein E(−/−) Mice Fed a High Fat/Cholesterol Diet. J Med Food 2011.
• [20]Voelkel NF, Tuder RM: Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest 2000, 106:733-738.
• [21]Zecchin HG, Priviero FB, Souza CT, Zecchin KG, Prada PO, Carvalheira JB, Velloso LA, Antunes E, Saad MJ: Defective insulin and acetylcholine induction of endothelial cell-nitric oxide synthase through insulin receptor substrate/Akt signaling pathway in aorta of obese rats. Diabetes 2007, 56:1014-1024.
• [22]Siddiqui AH, Hussain T: Enhanced AT1 receptor-mediated vasocontractile response to ANG II in endothelium-denuded aorta of obese Zucker rats. Am J Physiol Heart Circ Physiol 2007, 292:1722-1727.
• [23]Takase H, Moreau P, Küng CF, Nava E, Lüscher TF: Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Hypertension 1996, 27:25-31.
• [24]Bernal PJ, Leelavanichkul K, Bauer E, Cao R, Wilson A, Wasserloos KJ, Watkins SC, Pitt BR, St Croix CM: Nitric-oxide-mediated zinc release contributes to hypoxic regulation of pulmonary vascular tone. Circ Res 2008, 102:1575-1583.
• [25]Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, Richer C: Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:183-189.
• [26]Carvalheira JB, Ribeiro EB, Araújo EP, Guimarães RB, Telles MM, Torsoni M, Gontijo JA, Velloso LA, Saad MJ: Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats. Diabetologia 2003, 46:1629-1640.
• [27]Saad MJ, Velloso LA, Carvalho CR: Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J 1995, 310:741-744.
• [28]Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW: Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol 1997, 17:1707-1715.
• [29]Gotto AM Jr: Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation 2001, 103:2213-2218.
• [30]Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ: Safety and tolerability of dalcetrapib. Am J Cardiol 2009, 104:82-91.
• [31]Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM: Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370:1907-1914.
• [32]Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC: Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157:352-360.
• [33]Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL: PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002, 40:866-871.
• [34]Endemann DH, Schiffrin EL: Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr Hypertens Rep 2004, 6:85-89.
• [35]Vink H, Constantinescu AA, Spaan JA: Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion. Circulation 2000, 101:1500-1502.
• [36]Entman ML, Youker K, Shappell SB, Siegel C, Rothlein R, Dreyer WJ, Schmalstieg FC, Smith CW: Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism. J Clin Invest 1990, 85:1497-1506.
• [37]Scalia R, Salomon MG, Lefer AM: Characterization of thrombin-induced leukocyte endothelial cell interaction in the rat mesenteric microvasculature. Cardiovasc Pathobiol 1997, 1:160-166.
• [38]Sasakawa T, Sasakawa Y, Masunaga T, Fujitsu T, Hirayama Y, Ohkubo Y, Mutoh S: FK506 suppresses E-selectin, ICAM-1 and VCAM-1 expression on vascular endothelial cells by inhibiting tumor necrosis factor alpha secretion from peripheral blood mononuclear cells. Cytokine 2005, 29:67-71.
• [39]Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251-262.
• [40]Newby AC: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85:1-31.
• [41]Guo H, Shi Y, Liu L, Sun A, Xu F, Chi J: Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Arch Med Res 2009, 40:345-351.